CCL2 and systemic sclerosis: The preliminary report of a phase II randomised controlled trial of zibotentan, an endothelin-A antagonist, in SSc-CKD did find a statistical change in urinary MCP-1 and stabilisation of estimated glomerular filtration rate (eGFR) [35].